Onesource Specialty Pharma Ltd

Onesource Specialty Pharma Ltd

The company, Onesource Specialty Pharma Ltd, has allotted 900 equity shares of Re. 1 each under the OneSource ESOP 2021 plan to eligible employees, increasing the paid-up share capital from INR 11,46,72,891 to INR 11,46,73,791.

Onesource Specialty Pharma Ltd

Onesource Specialty Pharma Ltd has announced the closure of its trading window for the quarter ended September 30, 2026, until 48 hours after the declaration of financial results.

Onesource Specialty Pharma Ltd

Onesource Specialty Pharma Ltd has announced the voting results of its 19th AGM, with all resolutions passed with significant majority. The company's shareholders have approved the adoption of financial statements, re-appointment of Neeraj Sharma as Director, and appointment and fixation of remuneration of Statutory Auditors.

ONESOURCE SPECIALTY PHARMA LIMITED

Onesource Specialty Pharma has informed BSE about the appointment of a new Statutory Auditor.

ONESOURCE SPECIALTY PHARMA LIMITED

Onesource Specialty Pharma Limited has informed the BSE about the appointment of a new Statutory Auditor.

ONESOURCE SPECIALTY PHARMA LIMITED

Onesource Specialty Pharma Limited has informed BSE about the appointment of a new statutory auditor.

ONESOURCE SPECIALTY PHARMA LIMITED

Onesource Specialty Pharma Limited has informed BSE about the appointment of a new Statutory Auditor.

ONESOURCE SPECIALTY PHARMA LIMITED

ONESOURCE SPECIALTY PHARMA LIMITED has informed BSE about the appointment of a new Statutory Auditor.

ONESOURCE SPECIALTY PHARMA LIMITED

ONESOURCE SPECIALTY PHARMA LIMITED has informed BSE about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent. The company has appointed a new Statutory Auditor.

ONESOURCE SPECIALTY PHARMA LIMITED

Onesource Specialty Pharma Limited has informed BSE about the appointment of a new statutory auditor.

ONESOURCE SPECIALTY PHARMA LIMITED

Onesource Specialty Pharma Limited has informed BSE about the appointment of a new statutory auditor.

ONESOURCE SPECIALTY PHARMA LIMITED

Onesource Specialty Pharma Limited has informed BSE about the appointment of a new Statutory Auditor.

Onesource Specialty Pharma Ltd

Onesource Specialty Pharma Ltd has appointed M/s BSR and Co. LLP as its statutory auditors for a term of 5 consecutive years.

Onesource Specialty Pharma Ltd

OneSource Specialty Pharma Ltd held its 19th Annual General Meeting (AGM) on September 23, 2026, through video conference. The meeting was attended by 81 shareholders holding 3,46,04,605 shares. The company's CEO, Neeraj Sharma, briefed the shareholders on the company's performance for the financial year ended March 31, 2026, and provided key strategic updates.

Onesource Specialty Pharma Ltd

Onesource Specialty Pharma Ltd has announced an investor presentation on September 03, 2026, and has uploaded the latest presentation on its website.

Onesource Specialty Pharma Ltd

Onesource Specialty Pharma Ltd has published a newspaper advertisement confirming the dispatch of the notice convening the 19th AGM and Remote e-voting.

Onesource Specialty Pharma Ltd

Onesource Specialty Pharma Ltd has announced the 19th AGM (2nd AGM after listing) to be held on September 23, 2026, through video conferencing. The company has also released its Integrated Annual Report for the financial year 2025-26.

Onesource Specialty Pharma Ltd

Onesource Specialty Pharma Ltd has submitted its Business Responsibility and Sustainability Report (BRSR) for FY26, as per SEBI regulations.

Onesource Specialty Pharma Ltd

Onesource Specialty Pharma Ltd has announced its Annual Report for FY 2025-26, including the Notice of the 19th AGM and Integrated Annual Report. The report highlights the company's strategy, customer partnerships, and multi-modality platform.

Onesource Specialty Pharma Ltd

Onesource Specialty Pharma Ltd has announced its Annual Report for FY 2025-26, including the Notice of the 19th AGM and Integrated Annual Report, which highlights the company's performance, strategy, and future plans.